|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and more than 2,300 generic ingredients from more than 1,700 branded and generic pharmaceutical companies, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: DIOVAN HCT
Summary for Tradename: DIOVAN HCT
|
|
Latest news for DIOVANNovartis Boost Seen in Fast Approvals as Protection Ends5 May 2013, 6:20 pm Japanese Research Scandal Expands To A Second Trial And A Novartis Employee2 May 2013, 4:48 pm Novartis posts profit gain thanks to new drugs27 April 2013, 11:28 am U.S. Joins Shepherd, Finkelman, Miller & Shah, LLP Whistleblower Lawsuit Against Novartis Pharmaceuticals Corporation26 April 2013, 4:56 pm Novartis posts 6.7 per cent net profit gain in first quarter on drug launches, approvals24 April 2013, 3:27 pm Novartis Boosted by Drug Launches24 April 2013, 7:06 am Novartis seeks productivity improvements with Harry Kirsch as new CFO24 April 2013, 2:28 am Novartis names Harry Kirsch new CFO24 April 2013, 2:13 am Novartis Profit Rises 7% on Lack of Generic Diovan24 April 2013, 1:35 am Courtesy of Yahoo News | ||||||
Clinical Trials for: DIOVAN HCTLong Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study) Status: Completed Condition: Hypertension A Study of VAH631 in Patients With Essential Hypertension (Factorial Study) Status: Completed Condition: Hypertension A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients Status: Completed Condition: Hypertension Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension Status: Completed Condition: Hypertension Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension Status: Completed Condition: Hypertension SMOOTH - Blood Pressure Control in Diabetic/Obese Patients Status: Completed Condition: Hypertension; Diabetes Mellitus, Type 2 Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Patients With Slight Hypertension and Target Organ Damage Status: Completed Condition: Hypertension; Ventricular Remodeling; Erectile Dysfunctions Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP) Status: Completed Condition: Hypertension Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide (Double Doses) Status: Completed Condition: Healthy Normotensive Participants Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide Status: Completed Condition: Healthy Normotensive Participants Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Exclusivity Expiration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | DIOVAN HCT | hydrochlorothiazide; valsartan | TABLET; ORAL | 020818 | Apr 28, 2006 | RX | No | 5,399,578*PED | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Novartis | DIOVAN HCT | hydrochlorothiazide; valsartan | TABLET; ORAL | 020818 | Apr 28, 2006 | RX | No | 6,294,197*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Novartis | DIOVAN HCT | hydrochlorothiazide; valsartan | TABLET; ORAL | 020818 | Apr 28, 2006 | RX | Yes | 5,399,578*PED | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Novartis | DIOVAN HCT | hydrochlorothiazide; valsartan | TABLET; ORAL | 020818 | Apr 28, 2006 | RX | Yes | 6,294,197*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Paragraph IV activity for: DIOVAN HCT
| Drugname | Dosage | Strength | RLD | Submissiondate |
| valsartan and hydrochlorothiazide | Tablets | 320 mg/12.5 mg and 320 mg/25 mg | Diovan HCT | 2/7/2007 |
| valsartan and hydrochlorothiazide | Tablets | 80 mg/12.5 mg, 160 mg/12.5 mg and 160 mg/25 mg | Diovan HCT | 12/2/2005 |
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc